# NCT02315326 (NCT02315326)

> Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

No report yet. It can be ordered.

- Drugs tested: ibrutinib plus methotrexate plus rituximab; ibrutinib plus methotrexate plus rituximab plus procarbazine
- Indication: primary or secondary central nervous system lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02315326
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL); Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
- Interventions: Ibrutinib; HD- Methotrexate (MTX); Rituximab + HD- Methotrexate (MTX); procarbazine
- Enrollment: 93
- Primary outcome: define the Maximum Tolerated Dose (MTD) of ibrutinib (phase I)
- Primary outcome: progression free survival (phase II)
- Primary outcome: define the Maximum Tolerated Dose (MTD) of ibrutinib in combination with high-dose Methotrexate (HD-MTX)

## Indexed commentary on NCT02315326 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02315326
